The US Food and Drug Administration has approved Kynamro, a gene silencing drug from Isis Pharmaceuticals, to treat homozygous familial hypercholesterolemia, The New York Times reports. The drug will be marketed by Sanofi's Genzyme division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.